This document summarizes a study that developed Sanger sequencing panels covering cancer-related genes like TP53, KRAS, and NRAS to detect low-level somatic mutations in formalin-fixed paraffin-embedded (FFPE) tumor samples. The researchers confirmed variants identified by next-generation sequencing in FFPE lung cancer samples using their Sanger sequencing panels coupled with analysis software. They showed their method could reliably detect variants present at as little as 3% and using DNA amounts as low as 0.1 ng. This simple and affordable Sanger sequencing approach provides a useful screening method for detecting somatic mutations in clinical cancer samples where limited DNA is available.